 |
6 Products |  |
6 Diseases | | 6 Products |
|
995 Trials |  |
3123 News |  |
| «12...41424344454647484950515253» |
- | decitabine / Generic mfg.
New P2 trial: Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Apr 19, 2020
P2, N=29, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: MAPAC: Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma (clinicaltrials.gov) - Apr 16, 2020
P2, N=60, Recruiting, Sponsor: Peking University People's Hospital
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial initiation date: TRIPLET: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (clinicaltrials.gov) - Apr 15, 2020
P2, N=84, Recruiting, Sponsor: Sun Yat-sen University
Initiation date: Dec 2019 --> Apr 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Camrelizumab Combined With Apatinib ?XELOX ?RFA in the Treatment of Liver Metastases of Colorectal Cancer (clinicaltrials.gov) - Apr 15, 2020
P1/2, N=23, Recruiting, Sponsor: Zhongshan Hospital Xiamen University
Initiation date: Dec 2019 --> Apr 2020 Not yet recruiting --> Recruiting
- ||||| AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Apr 14, 2020
P2, N=205, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- CG-806 / Aptose Biosci, CrystalGenomics, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
[VIRTUAL] Early clinical findings from a phase 1a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or refractory CLL/SLL or non-Hodgkin’s lymphomas (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_420;
P1
There have been no TEAE. Oral absorption was sufficient to produce plasma concentrations in humans approaching exposures known to be effective in murine leukemia models.
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab plus apatinib in extensive-stage small-cell lung cancer (PASSION): A multicenter, two-stage, phase 2 trial (Virtual Meeting: All Session Times Are U.S. EDT) - Apr 13, 2020 - Abstract #AACRI2020AACR-I_10;
P2
Camrelizumab plus apatinib showed potent antitumor activity in both chemo-sensitive and chemo-resistant ED-SCLC pts after platinum-based chemotherapy with acceptable toxicity profile. This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer (clinicaltrials.gov) - Apr 13, 2020
P2, N=30, Active, not recruiting, Sponsor: Beijing Friendship Hospital
- |||||||||| AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial, PD(L)-1 Biomarker: Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC (clinicaltrials.gov) - Apr 12, 2020
P3, N=550, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- |||||||| AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Apr 12, 2020
P3, N=56, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Enrollment change, Trial primary completion date: A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects (clinicaltrials.gov) - Apr 9, 2020
P1, N=126, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC. Active, not recruiting --> Completed | N=45 --> 126 | Trial primary completion date: Aug 2019 --> Nov 2019
- ||||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment closed: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 8, 2020
P3, N=250, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed | N=45 --> 126 | Trial primary completion date: Aug 2019 --> Nov 2019 Recruiting --> Active, not recruiting
- | AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, New P2 trial, PD(L)-1 Biomarker: PKUCH-R04: Total Neoadjuvant Treatment Plus SHR1210 for High-risk Rectal Cancer and Biomarker Screening Base on Neoantigen (clinicaltrials.gov) - Apr 8, 2020
P2, N=25, Recruiting, Sponsor: Beijing Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC (clinicaltrials.gov) - Apr 7, 2020
P2, N=94, Recruiting, Sponsor: Tang-Du Hospital
- | Epidaza (chidamide) / Chipscreen
New P1/2 trial: Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor (clinicaltrials.gov) - Apr 6, 2020
P1/2, N=100, Recruiting, Sponsor: Chinese PLA General Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial initiation date, Trial primary completion date: Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 5, 2020
P2/3, N=180, Not yet recruiting, Sponsor: Shanghai Proton and Heavy Ion Center
Recruiting --> Active, not recruiting Initiation date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2024 --> May 2024
- |||||||||| AiTan (rivoceranib) / HLB Bio Group
New P3 trial: A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov) - Apr 5, 2020
P3, N=780, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: ACCORD: Adjuvant Immunotherapy Combined With Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer (clinicaltrials.gov) - Apr 2, 2020
P2, N=92, Not yet recruiting, Sponsor: Sun Yat-sen University
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker: Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma (clinicaltrials.gov) - Apr 1, 2020
P2, N=40, Not yet recruiting, Sponsor: Di Wu
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Apr 1, 2020
P2, N=46, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Initiation date: Feb 2020 --> May 2020 | Trial primary completion date: Feb 2024 --> May 2024 Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma (clinicaltrials.gov) - Mar 24, 2020
P2, N=43, Not yet recruiting, Sponsor: West China Hospital
- || Afinitor (everolimus) / Novartis, Acelex (polmacoxib) / CrystalGenomics, Daewoong Pharma
Clinical, Journal: An unusual case of colon perforation with multiple transmural ulcers after use of polmacoxib and everolimus in a metastatic breast cancer patient: A case report. (Pubmed Central) - Mar 19, 2020
Intestinal perforation has not been reported previously as a complication of everolimus, and perforation of the lower intestinal tract caused by a selective COX2 inhibitor is extremely rare. We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial primary completion date: FZPL-Ib-105: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC (clinicaltrials.gov) - Mar 19, 2020
P1, N=52, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
We present here a case of colon perforation that occurred after use of polmacoxib in a metastatic breast cancer patient who had been treated with everolimus for the preceding six months. Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Apr 2021
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker: A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC (clinicaltrials.gov) - Mar 17, 2020
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial completion date: Dec 2020 --> Aug 2021 | Trial primary completion date: Dec 2019 --> Apr 2021 N=58 --> 40 | Trial primary completion date: Jun 2020 --> Aug 2019
- | doxorubicin hydrochloride / Generic mfg.
Retrospective data, Journal: Safety and Efficacy of PD-1 Inhibitors Plus Chemotherapy in Advanced Soft Tissue Sarcomas: A Retrospective Study. (Pubmed Central) - Mar 13, 2020
This study provides preliminary evidence that the combination of doxorubicin chemotherapy and PD-1 inhibitor for advanced STS is safe and effective. We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas.
- | AiTan (rivoceranib) / HLB Bio Group, Halaven (eribulin mesylate) / Eisai, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Immuno2020-01: A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC (clinicaltrials.gov) - Mar 11, 2020
P2, N=46, Not yet recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- | Endostar (recombinant human endostatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC (clinicaltrials.gov) - Mar 10, 2020
P2, N=52, Recruiting, Sponsor: Beijing Cancer Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Enrollment open, Trial primary completion date: A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) (clinicaltrials.gov) - Mar 9, 2020
P2, N=46, Recruiting, Sponsor: Fudan University
We plan to conduct randomized clinical trials to confirm and characterize the activity of the chemotherapy-immunotherapy combinations in the treatment of sarcomas. Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2020 --> Jan 2021
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) - Mar 9, 2020
P2, N=25, Recruiting, Sponsor: Fudan University
- | AiRuiKa (camrelizumab) / HLB Bio Group, Cosentyx (secukinumab) / Novartis
New P1/2 trial: A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC?SHR-1210-AIN457? (clinicaltrials.gov) - Mar 6, 2020
P1/2, N=40, Not yet recruiting, Sponsor: Yanqiao Zhang
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 5, 2020
P2, N=20, Recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma (clinicaltrials.gov) - Mar 4, 2020
P2, N=75, Recruiting, Sponsor: Sun Yat-sen University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Mar 4, 2020
P2, N=80, Not yet recruiting, Sponsor: Huazhong University of Science and Technology
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery (clinicaltrials.gov) - Mar 4, 2020
P2, N=67, Recruiting, Sponsor: Shanghai Zhongshan Hospital
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
Clinical, Journal: Anti-PD-1 Antibody SHR-1210 combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. (Pubmed Central) - Mar 2, 2020
SHR-1210 and apatinib combination therapy demonstrated manageable toxicity in HCC and GC/EGJC patients at recommended single-agent doses of both drugs. The RP2D for apatinib as combination therapy was 250 mg, which showed encouraging clinical activity in patients with advanced HCC.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab Combined With Local Treatment in NSCLC Patients With BM (clinicaltrials.gov) - Mar 1, 2020
P2, N=20, Not yet recruiting, Sponsor: Zhejiang Cancer Hospital
- AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab plus apatinib in patients with advanced cervical cancer: A multicenter, open-label, single-arm, phase II trial. (Poster Board 192) - Feb 27, 2020 - Abstract #ASCO2020ASCO_583;
P2
Research Funding: Jiangsu Hengrui Medicine Co. Ltd., National Natural Science Foundation of China.
- fluorouracil / Generic mfg., AiRuiKa (camrelizumab) / Incyte
[VIRTUAL] Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma. (Poster Board 144) - Feb 27, 2020 - Abstract #ASCO2020ASCO_425;
P2
Camrelizumab combined with FOLFOX as neoadjuvant regimen in patients with locally advanced GC/GEJC showed promising pCR with good tolerance. Research Funding: Jiangsu Hengrui Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC (clinicaltrials.gov) - Feb 27, 2020
P2, N=40, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial: Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer (clinicaltrials.gov) - Feb 27, 2020
P1/2, N=52, Not yet recruiting, Sponsor: China Medical University, China
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor (clinicaltrials.gov) - Feb 24, 2020
P2, N=180, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment open, PD(L)-1 Biomarker, IO biomarker: Neoadjuvant Immunotherapy for Resectable Gastric Cancer (clinicaltrials.gov) - Feb 18, 2020
P2, N=30, Recruiting, Sponsor: Qilu Hospital of Shandong University
Research Funding: Jiangsu Hengrui Medicine Co., Ltd. Not yet recruiting --> Recruiting
- AiTan (rivoceranib) / HLB Bio Group, camrelizumab (INCSHR1210) / Incyte
Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_390;
- camrelizumab (INCSHR1210) / Incyte
A phase I clinical study to investigate the safety, tolerability and pharmacokinetics of PD-1 antibody Camrelizumab (SHR-1210) in patients with solid tumor: the results of Non-small cell lung cancer cohort. (Hall 1) - Feb 15, 2020 - Abstract #ELCC2020ELCC_377;
- | Zadaxin (thymalfasin) / SciClone, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Immunoregulatory Therapy for 2019-nCoV (clinicaltrials.gov) - Feb 13, 2020
P2, N=120, Not yet recruiting, Sponsor: Southeast University, China
- | AiTan (rivoceranib) / HLB Bio Group, Aqupla (nedaplatin) / Simcere, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer (clinicaltrials.gov) - Feb 11, 2020
P2, N=45, Recruiting, Sponsor: Chinese Academy of Medical Sciences
Not yet recruiting --> Recruiting N=30 --> 45
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial primary completion date: APFAO: Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma (clinicaltrials.gov) - Feb 6, 2020
P2, N=43, Completed, Sponsor: Peking University People's Hospital
N=30 --> 45 Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Oct 2019
- | AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
Biomarker, Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker: EBAOFC: Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab (clinicaltrials.gov) - Feb 6, 2020
P=N/A, N=40, Recruiting, Sponsor: Peking University People's Hospital
Active, not recruiting --> Completed | Trial primary completion date: Mar 2019 --> Oct 2019 Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Initiation date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Jun 2021
- | AiTan (rivoceranib) / HLB Bio Group, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer (clinicaltrials.gov) - Feb 6, 2020
P2, N=30, Not yet recruiting, Sponsor: Beijing Friendship Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial primary completion date: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Hypofraction Radiotherapy in Patients With NSCLC (clinicaltrials.gov) - Feb 5, 2020
P2, N=42, Recruiting, Sponsor: Shandong Cancer Hospital and Institute
Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Dec 2021 | Initiation date: Jun 2019 --> Dec 2019 | Trial primary completion date: Jun 2020 --> Jun 2021 Trial primary completion date: Jul 2019 --> Jul 2020